Who
Mark Howard Snyder
SVP, Chief Legal Officer
Company insider
Files Form 4 as: SVP, Chief Legal Officer, Halozyme Therapeutics.
In numbers
- Trades disclosed
- 83
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 3 Jan 2022
- Last trade
- 12 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 15 Jun 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,034 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code F | $189K2,715 at $69.50 | filing |
| 12 Jun 2026filed 15 Jun 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,034 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,034 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,034 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code F | $189K2,715 at $69.50 | filing |
| 23 Feb 2026filed 24 Feb 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code M | —7,011 at $0.00 | filing |
| 23 Feb 2026filed 24 Feb 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,011 at $0.00 | filing |
| 23 Feb 2026filed 24 Feb 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code F | $267K3,782 at $70.64 | filing |
| 23 Feb 2026filed 24 Feb 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,011 at $0.00 | filing |
| 23 Feb 2026filed 24 Feb 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code M | —7,011 at $0.00 | filing |
| 23 Feb 2026filed 24 Feb 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code F | $267K3,782 at $70.64 | filing |
| 20 Feb 2026filed 24 Feb 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,332 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code F | $204K2,876 at $70.98 | filing |
| 20 Feb 2026filed 24 Feb 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,332 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,332 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,332 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code F | $204K2,876 at $70.98 | filing |
| 16 Feb 2026filed 17 Feb 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code M | —4,796 at $0.00 | filing |
| 16 Feb 2026filed 17 Feb 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code F | $206K2,587 at $79.44 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.